A Phase II Trial of BAY86-9766 Plus Sorafenib as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC).
Phase of Trial: Phase II
Latest Information Update: 07 Oct 2014
At a glance
- Drugs Refametinib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms BASIL
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jun 2013 Planned End Date changed from 1 Jan 2014 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 10 May 2013 Planned End Date changed from 1 Jun 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.